Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorCenters for Medicare and Medicaid Services/ Coverage and Analysis Group
About this trial
The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).
Eligibility criteria
Qualifiers
Medicare patients with a clinical diagnosis of mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD.
Disqualifiers
none
Trial design
Treatments tested in this trial
- Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease
Treatment groups
No treatment groups listed
Locations
1Centers for Medicare and Medicaid Services21244, BaltimoreMaryland, United States
Sponsors and collaborators
Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
Lead sponsor
Source ClinicalTrials.gov